2018 Accepted Abstracts
Please note that abstracts have not been edited by CMHC staff for content, style, or accuracy, and are displayed as input by each submitter.
001. Cardioprotective effect of liraglutide is amplified with anti-inflammatory and decreased brain natriuretic peptide levels, in addition to glycemia and body weight reduction.
Thursday, October 25, 2018
Piljac A1, Jazbec A2, Duvnjak L1, Ljubic S1
1 Clinical Hospital Merkur, University Clinic Vuk Vrhovac, Zagreb, Croatia;
2 University of Zagreb, Zagreb, Croatia
002. Effect of Royal Jelly Intake on Serum Glucose, Apolipoprotein A-I (ApoA-I), Apolipoprotein B (ApoB) and ApoB/ApoA-I Ratios in Patients with Type 2 Diabetes: A Randomized, Double-Blind Clinical Trial Study.
Thursday, October 25, 2018
Farzad Shidfar1,2, Basmeh Khoshpey1, Shima Djazayeri1, Fatemeh Amiri 1, Mojtaba Malek 2, Agha Fatemeh Hosseini 3, Sharieh Hosseini 4, Shahrzad Shidfar5
1 Department of Nutrition, School of Public Health, Iran University of Medical Sciences, Tehran, Iran;
2 Cardiovascular Research Center, Institute of Endocrine and Metabolism, Iran University of Medical Sciences, Tehran, Iran;
3 Department of Statistics, School of Public Health, Iran University of Medical Sciences, Tehran, Iran;
4 Department of Applied Chemistry, Faculty of Pharmaceutical Chemistry, Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran;
5 Worcester Memorial Hospital, University of Massachusetts, Worcester, Massachusetts, USA.
003. Predictive value of epicardial fat volume for the presence of significant coronary artery Disease.
Friday, October 26, 2018
Eltamawy K, Mostafa H, Ahmad Fouad D
Assiut General Hospital (Ministry of Health), Assiut University Hospital, Qesm Than Asyut, Egypt
004. Takotsubo Cardiomyopathy in Chronic Kidney Disease patients: A systematic review.
Thursday, October 25, 2018
Kariyanna PT1, Borhanjoo P2, Jayarangaiah A3, McFarlane S2
1 Division of Cardiovascular Disease, Department of Internal Medicine, SUNY Downstate, Brooklyn, N.Y.
2 Department of Internal Medicine, SUNY Downstate, Brooklyn, N.Y.
3 Department of Internal Medicine, Wake Forest University - Baptist Health system, Winston Salem, N.C.
005. Type 2 diabetic patients and patients on basal supported oral therapy mainly benefit from introduction of insulin degludec.
Thursday, October 25, 2018
Ljubic S1,2, Piljac A1, Jazbec A2, Antal I1, Lea Duvnjak L1,2
1 Vuk vrhovac University Clinic, Merkur Clinical Hospital, Zagreb, Croatia;2 University of Zagreb, Zagreb, Croatia.
006. Cardiovascular Risk Reduction Associated with Pharmacological Weight Loss Therapy: A Meta-Analysis.
Friday, October 26, 2018
Kane JA, Munir I, Mehmood T, Kamran H, Yacoub M, Youssef I, Gustafson DR, McFarlane SI
SUNY Downstate Medical Center, Brooklyn, NY.
007. The effects of RYGB on tissue insulin sensitivity, beta cell function and post-meal glucose flux are maintained 7 years after surgery in both diabetic and non diabetic patients.
Thursday, October 25, 2018, 10:15 – 11:15 AM, 2:20 - 3:20 PM
M Palumbo1, B Astiarraga1, C Barbieri2, M Gaggini2, L Vecoli1, V Zampa3, M Anselmino5, A Mari2, A
Gastaldelli4, S Camastra1.
1 Department of Clinical and Experimental Medicine, University of Pisa;
2 Institute of Clinical Physiology, CNR, Pisa;
3 Radiodiagnostic Unit, Santa Chiara Hospital Pisa;
4 Bariatric Surgery Unit, Santa Chiara Hospital Pisa;
5 CNR, Padua.
008. Long-Term Effect of Patiromer for Hyperkalemia Treatment in Patients With HFmrEF and Diabetic Nephropathy on RAAS Inhibitors.
Thursday, October 25, 2018
Pitt B1, Mayo M2, Garza D2, Arthur S2, Lainscak M3
1 University of Michigan School of Medicine, Ann Arbor, MI, United States;
2 Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, United States;
3 General Hospital Murska Sobota, Murska Sobota, Slovenia.
009. Effect of Patiromer on Serum Potassium in Hyperkalemic Patients With and Without Obesity: Pooled Results from the AMETHYST-DN, OPAL-HK and TOURMALINE Trials.
Thursday, October 25, 2018
Rossignol P1, Gross C2, Mayo M2, Warren S2, Yuan J2, Budden J2, Morales E3
1 Centre d’Investigations Cliniques-Plurithématique, INSERM, Université de Lorraine, Nancy, France;
2 Relypsa, Inc., a Vifor Pharma Group Company, Redwood City, CA, United States;
3 Servicio de Nefrología, Hospital Universitario 12 de Octubre, Madrid, Spain.
010. Association of body mass index and diastolic function in metabolically healthy obese with preserved ejection fraction.
Friday, October 26, 2018
Rozenbaum Z, Topilsky Y, Laufer-Perl M
Department of Cardiology, Tel Aviv Medical Center, Israel; Affiliated to the Sackler Faculty of Medicine, Tel Aviv University.
011. Results of Intensive Weight Loss Program (IWLP) (non-surgical) in a primary care office. Comparison of IWLP and CDC Diabetes Prevention Program (CDC DPP).
Friday, October 26, 2018
Ahmed M1, Rader A2
1 Activate Healthcare, 2010 N. Damen Ave., Suite F, Chicago, IL 60647;
2 Idaho Weight Loss, 801 N. Stilson Rd. #200, Boise, ID 83703.
012. Lowered glucose levels and exogenous insulin requirements in T2DM and T1DM patients treated with oral insulin (ORMD-0801): Phase 2, randomized, placebo-controlled evaluations.
Thursday, October 25, 2018
Kidron M, Homer K, Neutel J
Oramed Pharmaceuticals, Jerusalem, Israel; Integrium, LLC, Cedar Knolls, NJ, USA; St. Joseph Hospital, Tustin, CA, USA.
013. Assessment of Cardiovascular Disease Risk And Therapeutic Patterns Among Urban Black Rheumatoid Arthritis Patients.
Thursday, October 25, 2018
McFarlane IM, Bhamra MS, Taklalsingh N, Kaplan I, Dellinger E, Smerling J, Lopez DL, Gondal I, Paltoo K, Trevisonno M
SUNY Downstate Medical Center; Health + Hospitals Kings County, Brooklyn, NY.
014. Comparative Effectiveness and Safety between Non-VKA Oral Anticoagulants in Non-valvular Atrial Fibrillation Patients: A Dose Subgroup Analysis of the ARISTOPHANES Study.
Friday, October 26, 2018
Lip GYH1, Keshishian A2, Li X3, Hamilton M3, Masseria C4, Dhamane A3, Luo X5, Mardekian J4, Friend K3, Nadkarni A3, Pan X6, Baser O7, Deitelzweig S8
1 Institute of Cardiovascular Sciences, University of Birmingham, United Kingdom; Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark;2 STATinMED Research, Ann Arbor, MI, USA;
3 Bristol-Myers Squibb Company, Lawrenceville, NJ, USA;
4 Pfizer, Inc., New York, NY, USA;
5 Pfizer, Inc., Groton, CT, USA;
6 Bristol-Myers Squibb Company, Wallingford, CT, USA;
7 Columbia University, New York, NY, USA;
8 Ochsner Clinic Foundation, Department of Hospital Medicine, New Orleans, LA, USA and The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA.
015. Differences in the Management of Acute Coronary Syndromes by Race and Proximity to Care in an Integrated Healthcare Delivery System in Northern Nevada.
Friday, October 26, 2018
Rowan C1, Metcalf J2, Grzymski J2, Mues KE3, Yedigarova L3, Woo C3, Williams KA4
1 Renown Institute for Heart & Vascular Health, Reno, NV;
2 Desert Research Institute, Las Vegas, NV;
3 Amgen Inc, Thousand Oaks, CA;
4 Rush University, Chicago, IL.
A division of Tarsus Medical owned by Tarsus Group
Cardiometabolic Health Congress.
All Rights Reserved.
